Insider Cluster (2 insiders) ·Filed Jun 15, 2026

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $766K total
Actionable Insight • Neutral

This cluster is too small to warrant a trading signal. Monitor for any upcoming corporate events (earnings, pipeline updates) that could explain the sales, but the dollar amounts are routine and non-informative.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CYTK ▼ -2.11% at T+60d
NEUTRAL call ✗ call lost -2.11% · α vs SPY -3.11% · entry $75.21 → $73.62
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
+3.86%
call +3.86% · α +5.10%
$78.11
settled 4mo ago
T+5d
+6.38%
call +6.38% · α +8.61%
$80.01
settled 3mo ago
T+20d
+8.94%
call +8.94% · α +8.74%
$81.93
settled 3mo ago
T+60d
-2.11%
call -2.11% · α -3.11%
$73.62
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Two CYTK insiders, including the CEO and EVP of R&D, sold a combined $766K in open-market transactions over a week. The total represents just 0.009% of the $8.7B market cap, making this a routine, immaterial cluster with no predictive signal.

Key Financial Metrics

Direction
selling
Total Value
$766.0K
Insiders
2

Key Facts

  • CEO Robert Blum sold 7,500 shares at $70.46 for $528,450 on June 15, 2026.
  • EVP Fady Malik sold 3,500 shares at $67.98 for $237,930 on June 9, 2026, after exercising options.
  • Total insider sales of $766K represent ~0.009% of CYTK's $8.7B market cap.
  • Both sales are trivial relative to company size and likely liquidity-driven.

Financial Impact

Total insider sales of $766K, immaterial relative to $8.7B market cap.

dilutioninsider ownership

Risk Factors

  • No material risk from this cluster; further insider selling above 0.5% of market cap would be more notable.
  • Historical model performance on CYTK shows poor predictive accuracy (25% win rate at T+20), suggesting caution on any directional call.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (28 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1781556160610
32 reports for CYTK
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+20▲ +10.38%Mar 31, 2026
Filters
Rows
Reports for CYTK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$69.31 $67.59▲ +2.48%▲ +4.59%$65.60 (+5.35%)
Sep 11, 2026
20d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.45 $67.56▼ −6.75%▼ −6.86%$65.60 (−9.45%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 29, 2026
4w ago
Press Release
BULLISH ★ 7/10
$70.91 $75.35▲ +6.26%▲ +6.40%$65.60 (−7.49%)
Aug 28, 2026
5w ago
8-K
BULLISH ★ 7/10
$72.09 $72.72▲ +0.87%▲ +0.76%$65.60 (−9.00%)
Jul 30, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.42 $81.37▲ +1.18%▼ −2.44%$65.60 (−18.43%)
Jul 27, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.62 $77.13▼ −4.33%▼ −5.40%$65.60 (−18.63%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$80.74 $80.42▼ −0.40%▼ −0.77%$65.60 (−18.75%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.93 $79.11▼ −3.44%▼ −2.15%$65.60 (−19.93%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 15, 2026